Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Liabilities and Shareholders Equity (2024 - 2025)

Historic Liabilities and Shareholders Equity for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $94.8 million.

  • Prelude Therapeutics' Liabilities and Shareholders Equity fell 5195.47% to $94.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $526.4 million, marking a year-over-year change of. This contributed to the annual value of $175.5 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Prelude Therapeutics reported Liabilities and Shareholders Equity of $94.8 million as of Q3 2025, which was down 5195.47% from $114.9 million recorded in Q2 2025.
  • Prelude Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $247.1 million during Q1 2024, with a 5-year trough of $94.8 million in Q3 2025.